Saman Rostambeigi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Saman Rostambeigi has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Azin Alizadehasl
Cardio‐Oncology Research Center Rajaie Cardiovascular Medical and Research Institute Tehran Iran
3 shared publications - Anita M. Kelsey
Division of Cardiology and Duke Heart Center, Duke University Medical Center, Durham, England
2 shared publications - Anita Sadeghpour
Cardiovascular Core Labs, MedStar Health, Georgetown University
2 shared publications - Homa Mazaherinia
Rajaie Cardiovascular, Medical, and Research Center, Iran University of Medical Sciences, Cardiologist, Tehran, Iran
2 shared publications - Khashayar Farnoud
Liver Transplantation Research Center, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
2 shared publications - Negin Mahmoudi Hamidabad
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA
2 shared publications
Latest Publications
- Open Access
- 18 June 2024
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 24 (1) , 1-8
Impact of commissural calcification on clinical outcome of percutaneous balloon mitral valvuloplasty; a retrospective cohort study of 876 patients
Background: Percutaneous balloon mitral valvuloplasty (PBMV) is the ACC/AHA class I recommendation for treating symptomatic rheumatic mitral stenosis with suitable valve morphology, less than moderate MR and absence of left atrium clot. The mitral valve restenosis and significant mitral regurgitation (MR) are known adverse outcomes of PBMV. This study aimed to evaluate the outcomes of PBMV in patients with severe mitral stenosis and the effect of Commissural Calcification (CC) on the outcomes.Methods: In this single-center retrospective cohort study, 876 patients who underwent PBMV were categorized into three groups based on their Wilkins score (Group I: score ≤ 8, Group II: score 9–10, and Group III: score 11–12). Patients were evaluated before, early after PBMV and at 6- and 24-month follow-ups. Main clinical outcomes were defined as significant restenosis and or symptomatic significant MR (moderate to severe and severe MR) or candidate for mitral valve replacement (MVR). The outcomes were compared between patients with and without CC.Results: A total of 876 patients with mean age 46.4 ± 12.3 years (81.0% females) were categorized based on Wilkins score. 333 (38.0%) were in Group I, 501 (57.2%) were in Group II, and 42 (4.8%) were in Group III. CC was present in 175 (20.0%) of the patients, among whom 95 (54.3%) had calcification of the anterolateral commissure, 64 (36.6%) had calcification of the posteromedial commissure, and in 16 (9.1%) patients both commissures were calcified. There was a significant difference in Wilkins score between patients with and without CC (P < 0.001). CC was associated with higher odds of significant symptomatic MR at early and mid-term follow up (OR: 1.69, 95%CI 1.19–2.41,P = 0.003; and OR: 3.90, 95%CI 2.61–5.83,P < 0.001, respectively), but not with restenosis (P = 0.128). Wilkins Groups II and III did not show higher odds of significant symptomatic MR compared to Group I at early (II:P = 0.784; III:P = 0.098) and mid-term follow up (II:P = 0.216; III:P = 0.227). Patients in Wilkins Group II had higher odds of restenosis compared to Group I (OR: 2.96,95%CI: 1.35–6.27,P = 0.007).Conclusion: Commissural calcification (CC) is an independent predictor of the significant symptomatic MR (an important determinant of adverse outcome) following PBMV in the early and mid-term follow-up. Mitral valve restenosis occurs more in patients with higher Wilkins score compared to group I with score ≤ 8. Combined Wilkins score and CC should be considered for patient suitability for PBMV.
- 18 June 2024
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 24 (1) , 1-8
Open AccessImpact of commissural calcification on clinical outcome of percutaneous balloon mitral valvuloplasty; a retrospective cohort study of 876 patients
Background: Percutaneous balloon mitral valvuloplasty (PBMV) is the ACC/AHA class I recommendation for treating symptomatic rheumatic mitral stenosis with suitable valve morphology, less than moderate MR and absence of left atrium clot. The mitral valve restenosis and significant mitral regurgitation (MR) are known adverse outcomes of PBMV. This study aimed to evaluate the outcomes of PBMV in patients with severe mitral stenosis and the effect of Commissural Calcification (CC) on the outcomes.Methods: In this single-center retrospective cohort study, 876 patients who underwent PBMV were categorized into three groups based on their Wilkins score (Group I: score ≤ 8, Group II: score 9–10, and Group III: score 11–12). Patients were evaluated before, early after PBMV and at 6- and 24-month follow-ups. Main clinical outcomes were defined as significant restenosis and or symptomatic significant MR (moderate to severe and severe MR) or candidate for mitral valve replacement (MVR). The outcomes were compared between patients with and without CC.Results: A total of 876 patients with mean age 46.4 ± 12.3 years (81.0% females) were categorized based on Wilkins score. 333 (38.0%) were in Group I, 501 (57.2%) were in Group II, and 42 (4.8%) were in Group III. CC was present in 175 (20.0%) of the patients, among whom 95 (54.3%) had calcification of the anterolateral commissure, 64 (36.6%) had calcification of the posteromedial commissure, and in 16 (9.1%) patients both commissures were calcified. There was a significant difference in Wilkins score between patients with and without CC (P < 0.001). CC was associated with higher odds of significant symptomatic MR at early and mid-term follow up (OR: 1.69, 95%CI 1.19–2.41,P = 0.003; and OR: 3.90, 95%CI 2.61–5.83,P < 0.001, respectively), but not with restenosis (P = 0.128). Wilkins Groups II and III did not show higher odds of significant symptomatic MR compared to Group I at early (II:P = 0.784; III:P = 0.098) and mid-term follow up (II:P = 0.216; III:P = 0.227). Patients in Wilkins Group II had higher odds of restenosis compared to Group I (OR: 2.96,95%CI: 1.35–6.27,P = 0.007).Conclusion: Commissural calcification (CC) is an independent predictor of the significant symptomatic MR (an important determinant of adverse outcome) following PBMV in the early and mid-term follow-up. Mitral valve restenosis occurs more in patients with higher Wilkins score compared to group I with score ≤ 8. Combined Wilkins score and CC should be considered for patient suitability for PBMV.
- Open Access
- 14 September 2022
- Published by Springer Nature in Research Square
Effect of Commissural Calcification on Clinical Outcomes of Percutaneous Mitral Valvuloplasty
Background Percutaneous mitral valvuloplasty (PMV) is a safe and widely used treatment in patients with symptomatic rheumatic mitral stenosis. This study aimed to evaluate short-term and mid-term outcomes of PMV in patients with severe mitral stenosis and the effect of commissural calcifications on the outcomes. Methods Medical records of 961 patients after PMV were reviewed. All patients were evaluated using transthoracic echocardiography before and after 24 hours. Patients were divided into three subgroups based on their Wilkins score (group I: score ≤8, group II: score 9-10, and group III: score 11-12). Also, patients were divided into two subgroups based on the presence or absence of commissural calcification. Patients were evaluated before PMV, 24 hours after the procedure and were followed for 6 and 24 months to evaluate the short-term and mid-term outcomes. The echocardiographic measures (mitral valve area, indexed mitral valve index, mitral valve mean gradient, and pulmonary artery systolic pressure) were compared after PMV, and at 6 months and 24 month follow-ups. Main clinical outcomes (moderate and severe mitral regurgitation and restenosis) were compared between patients with and without commissural calcifications. Results:Mean age of the patients was 46.6 ± 12.2, and 81.7 % of patients (n=785) were females. Groups I, II, and III (based on Wilkins score) consisted of 353 (36.7%), 559 (58.1%), and 49 (5%) patients, respectively. Mitral valve area (MVA) and indexed MVA increased significantly in all three groups; in both short-term and mid-term follow-ups (pmoderate MR) did not differ statistically between the three groups. Commissural calcification was present in 190 patients (19.77%). Restenosis was significantly higher in the presence of commissural calcification (pConclusion Both Wilkins score and presence of commissural calcification are associated with a higher incidence of mitral valve restenosis. While there is no strong association between higher Wilkins scores and higher rates of significant mitral regurgitation, commissural calcification is associated with a higher rate of severe mitral regurgitation.
- 14 September 2022
- Published by Springer Nature in Research Square
Open AccessEffect of Commissural Calcification on Clinical Outcomes of Percutaneous Mitral Valvuloplasty
Background Percutaneous mitral valvuloplasty (PMV) is a safe and widely used treatment in patients with symptomatic rheumatic mitral stenosis. This study aimed to evaluate short-term and mid-term outcomes of PMV in patients with severe mitral stenosis and the effect of commissural calcifications on the outcomes. Methods Medical records of 961 patients after PMV were reviewed. All patients were evaluated using transthoracic echocardiography before and after 24 hours. Patients were divided into three subgroups based on their Wilkins score (group I: score ≤8, group II: score 9-10, and group III: score 11-12). Also, patients were divided into two subgroups based on the presence or absence of commissural calcification. Patients were evaluated before PMV, 24 hours after the procedure and were followed for 6 and 24 months to evaluate the short-term and mid-term outcomes. The echocardiographic measures (mitral valve area, indexed mitral valve index, mitral valve mean gradient, and pulmonary artery systolic pressure) were compared after PMV, and at 6 months and 24 month follow-ups. Main clinical outcomes (moderate and severe mitral regurgitation and restenosis) were compared between patients with and without commissural calcifications. Results:Mean age of the patients was 46.6 ± 12.2, and 81.7 % of patients (n=785) were females. Groups I, II, and III (based on Wilkins score) consisted of 353 (36.7%), 559 (58.1%), and 49 (5%) patients, respectively. Mitral valve area (MVA) and indexed MVA increased significantly in all three groups; in both short-term and mid-term follow-ups (pmoderate MR) did not differ statistically between the three groups. Commissural calcification was present in 190 patients (19.77%). Restenosis was significantly higher in the presence of commissural calcification (pConclusion Both Wilkins score and presence of commissural calcification are associated with a higher incidence of mitral valve restenosis. While there is no strong association between higher Wilkins scores and higher rates of significant mitral regurgitation, commissural calcification is associated with a higher rate of severe mitral regurgitation.
- Open Access
- 1 November 2020
- Published by Brieflands in Multidisciplinary Cardiovascular Annals
- Vol. 12 (1)
Correlation Between Left Atrial Appendage and Right Atrial Appendage Velocities in Different Pathologies and Normal Subjects
Keywords Correlation Velocity Left Atrial Appendage Right Atrial Appendage Atrial Dysfunction
- 1 November 2020
- Published by Brieflands in Multidisciplinary Cardiovascular Annals
- Vol. 12 (1)
Open AccessCorrelation Between Left Atrial Appendage and Right Atrial Appendage Velocities in Different Pathologies and Normal Subjects
Keywords Correlation Velocity Left Atrial Appendage Right Atrial Appendage Atrial Dysfunction